1167. Rubella Seroprevalence in an Unvaccinated Pregnant Population in Malatya, Turkey
Session: Poster Abstract Session: Public Health
Friday, October 9, 2015
Room: Poster Hall
Background: Controlling congenital rubella was, and still is, one of the prime targets of the World Health Organization. We wanted to define the rubella seroprevalence in pregnancy in Malatya, Turkey. This data would assist policy makers to decide when to implement rubella vaccination in fertile population.

Methods: Stratified probability proportional to size sampling methodology. A total of 824 pregnant women from 60 clusters were enrolled. After obtaining informed consent, participants’ socio-demographic and fertility characteristics were collected by interview questionnaire. All the tested women had no history of rubella vaccination.  Anti-rubella IgM and IgG titers were studied from blood samples by micro ELISA.

Results: Of the 803 samples tested for rubella antibodies, 753 cases (93.8%) had anti-rubella IgG positivity, indicating a past infection. Five of the pregnant women (0.6%) had both anti-rubella IgM and IgG positive results, suggesting a recent infection. The remaining 45 women (5.6%) were seronegative for both antibodies. Seroprevalence was not associated with age or urban/rural residency. All the five anti-rubella IgM positive women were in the second trimester of pregnancy.

Conclusion: As 5.6% of pregnant women were susceptible to rubella during pregnancy, and five of them had already had a recent infection, immunization efforts should be directed at earlier ages like infancy or adolescent period.

Ender Pehlivan, prof1, L Karaoglu, Prof1, Metehan Ozen, Professor2, Mehmet Tekerekoglu, Prof3 and MF Genc, Prof1, (1)Inonu, Malatya, Turkey, (2)Pediatrics, Acibadem University, Istanbul, Turkey, (3)Inonu University, Malatya, Turkey

Disclosures:

E. Pehlivan, None

L. Karaoglu, None

M. Ozen, None

M. Tekerekoglu, None

M. Genc, None

See more of: Public Health
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.